What Does Korea Need To Develop Blockbuster Drugs?
Paradigm Shift Needed To Reach Finish Line
A recent industry forum in South Korea heard expert views on the issues and strategies required to take the country over the finish line in the development of home-grown blockbuster, and to progress the big licensing-out deals reached over the past few years.
You may also be interested in...
After record venture capital activity around South Korean biotechs last year, the strong investment interest has persisted so far this year, with an increased number of companies receiving large-scale funding as the promising sector emerges amid the pandemic.
US-based, China-focused CANbridge moves into cholestatic liver disease and enzyme replacement therapy via two deals. Plus deals involving LegoChem, TransThera, Morepen, Daiichi Sankyo, Geneseeq, Innocare, Biosplice, Sirnaomics and Walvax.
Legislation that could thin the crowded generic market clears first parliamentary hurdle as brand and generic firms alike react to the recent generic quality issue raised by recent manufacturing incidences at some South Korean pharma firms.